Source - RNS
RNS Number : 6046A
J.P. Morgan Securities LLC
22 January 2020
 

Ap27

 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.          KEY INFORMATION

 

Name of exempt principal trader

J.P Morgan Securities LLC

Company dealt in

Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary Share

Date of dealing

21 January 2020

 

2.          INTERESTS AND SHORT POSITIONS

 

(a)         Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

 5,204,199                  1.58

 4,260,102                  1.30

(2) Derivatives (other than options)

 5,134,127                  1.56

 4,398,486                  1.34

(3) Options and agreements to purchase/sell

 1,020,839                  0.31

 705,539                  0.21

Total

 11,359,166                  3.45

 9,364,127                  2.85

             

 

 

(b)         Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.       DEALINGS (Note 3)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

20

2

4

1

1

1

2

1

1

14

39

1

1

45

1

242,840

1

1

18

15

25

5

91

31

1

25

2

13

2

21

2

70

24

 

40

39,199

87

192.0400 USD

192.3750 USD

192.4125 USD

192.4300 USD

192.4400 USD

192.4800 USD

192.4950 USD

192.5000 USD

192.5100 USD

192.5186 USD

192.5200 USD

192.5300 USD

192.5400 USD

192.5476 USD

192.5700 USD

192.5800 USD

192.6000 USD

192.6100 USD

192.6289 USD

192.6347 USD

192.6380 USD

192.6500 USD

192.6800 USD

192.6865 USD

192.6900 USD

192.7012 USD

192.7050 USD

192.7162 USD

192.7200 USD

192.7300 USD

192.7500 USD

192.7777 USD

192.9271 USD

 

192.0400 USD

192.5800 USD

192.6800 USD

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(USD)

(Note 4)

Equity Swaps

Long

20

 26,000

 192.0400

 192.5800

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities 

under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is 

referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)                    YES

 

 

Date of disclosure

22 January 2020

Contact name

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ap31

 

 

SUPPLEMENTAL FORM 38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Put Option

Put Option

Put Option

Put Option

Put Option

Put Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Written

Written

Written

Written

Purchased

Purchased

Written

Written

Written

Purchased

Purchased

Purchased

Purchased

300,000

5,000

233,402

261,411

233,402

261,411

10,000

100,363

100,363

20,000

300

100,363

100,363

150.00

140.00

104.11

108.45

104.11

108.45

170.00

104.11

108.45

185.00

190.00

104.11

108.45

American

American

European

European

European

European

American

European

European

American

American

European

European

19JUN20

19JUN20

23JAN20

23JAN20

23JAN20

23JAN20

21FEB20

23JAN20

23JAN20

21FEB20

21FEB20

23JAN20

23JAN20

 

 

 

 

Notes

 

1.       Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.       For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLLFLBFLXBBF
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.